- Home
- ZOM
ZOM
Zomedica Corp.
as 12-26-2024 4:00pm EST
Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. The company's product portfolio includes diagnostics and therapeutics that emphasize patient health and practice health. The company is focused on the final development and commercialization of its TRUFORMA platform, which detects thyroid disorders in dogs & cats and adrenal disorders in dogs. Its operations are comprised of two reportable segments namely Diagnostic and Therapeutic Devices. It earns the majority of revenue from the therapeutics segment.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | ANN ARBOR |
| Market Cap: | 117.6M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 5.1M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.06 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.12 - $0.22 | Next Earning Date: | 11-07-2024 |
| Revenue: | $26,727,000 | Revenue Growth: | 11.33% |
| Revenue Growth (this year): | 36.75% | Revenue Growth (next year): | 14.92% |
Stock Insider Trading Activity of Zomedica Corp. (ZOM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Blair Anthony K | ZOM | COO | Nov 12 '24 | Buy | $0.12 | 150,000 | $18,450.00 | 400,000 | |
| POWERS JOHNNY D | ZOM | Director | Nov 11 '24 | Buy | $0.12 | 100,000 | $12,100.00 | 2,425,000 | |
| HEATON LARRY C II | ZOM | CEO | Nov 11 '24 | Buy | $0.12 | 100,000 | $12,200.00 | 500,000 | |
| Klass Russell Kevin | ZOM | Vice President of Sales | Nov 11 '24 | Buy | $0.12 | 500,000 | $60,289.80 | 1,210,250 |
Latest Zomedica Corp. News
ZOM Breaking Stock News: Dive into ZOM Ticker-Specific Updates for Smart Investing
ACCESSWIRE
4 days ago
Zomedica Launches Two New Quantitative Assays on the TRUFORMA(R) Platform: Canine NT-proBNP and Progesterone
ACCESSWIRE
8 days ago
Zomedica Appoints Scott A. Jordan Executive Vice President, Finance & Chief Financial Officer
ACCESSWIRE
a month ago
Zomedica to Present at the NobleCon20 Twentieth Annual Emerging Growth Equity Conference December 4, 2024
Argus Research
a month ago
Daily – Vickers Top Insider Picks for 11/20/2024
Argus Research
a month ago
Daily – Vickers Top Insider Picks for 11/19/2024
Argus Research
a month ago
Daily – Vickers Top Insider Picks for 11/18/2024
Argus Research
a month ago
Daily – Vickers Top Insider Picks for 11/15/2024
Argus Research
a month ago
Daily – Vickers Top Insider Picks for 11/14/2024
Compare ZOM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ZOM Zomedica Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.